Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)-Reference-Cited by-同舟云学术

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)

Published:2018-07-11 Issue:1 Volume:6 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Ascierto Paolo A.^ORCID,Brugarolas James,Buonaguro Luigi,Butterfield Lisa H.,Carbone David,Daniele Bruno,Ferris Robert,Fox Bernard A.,Galon Jérôme,Gridelli Cesare,Kaufman Howard L.,Klebanoff Christopher A.,Melero Ignacio,Nathan Paul,Paulos Chrystal M.,Ruella Marco,Sullivan Ryan,Zarour Hassane,Puzanov Igor

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-018-0377-z.pdf

Reference78 articles.

1. Feng Z, Bethmann D, Kappler M, Ballesteros-Merino C, Eckert A, Bell RB, et al. Multiparametric immune profiling in HPV- oral squamous cell cancer. JCI Insight. 2017;2. pii: 93652.

2. Twitty CG, Jensen SM, Hu HM, Fox BA. Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism. Clin Cancer Res. 2011;17:6467–81.

3. Sanborn RE. Randomized Ph II trial of allogeneic DPV-001 cancer vaccine alone or with adjuvant for curatively-treated stage III NSCLC (ID 4640). WCLC, 2016. P2.02-043.

4. Fox BA, Boulmay BC, Li R, Happel KT, Paustian C, Moudgil TL. T cell population expansion in response to allogeneic cancer vaccine alone (DPV-001) or with granulocyte-macrophage colony-stimulating factor (GM-CSF) or imiquimod (I) for definitively-treated stage III NSCLC patients (pts). J Clin Oncol. 2017;35(15_suppl) https://doi.org/10.1200/JCO.2017.35.15_suppl.e14639 .

5. Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M, et al. Signaling through OX40 enhances anti-tumor immunity. Semin Oncol. 2010;37:524–32.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors;Expert Opinion on Investigational Drugs;2022-08-03

2. All‐In‐One Biomimetic Nanoplatform Based on Hollow Polydopamine Nanoparticles for Synergistically Enhanced Radiotherapy of Colon Cancer;Small;2022-02-12

3. Immunomodulatory properties of nanostructured systems for cancer therapy;Journal of Biomedical Materials Research Part A;2022-01-19

4. Leukotriene B4 receptor 2 correlates with prognosis and immune infiltration in clear cell renal cell carcinoma;Investigational New Drugs;2021-10-11

5. The diterpenoid adenanthin upregulates the expression of natural killer group 2D receptor ligands in hepatocellular carcinoma cells;Molecular and Cellular Probes;2021-10